发明授权
- 专利标题： Method for predicting the response of melanoma patients to targeted pharmacotherapy
-
申请号： US15572220申请日： 2016-05-20
-
公开(公告)号： US10604786B2公开(公告)日： 2020-03-31
- 发明人: Robby Ruijtenbeek , Liesbeth Coosje Hovestad-Bijl
- 申请人： PAMGENE BV
- 申请人地址： NL 's-Hertogenbosch
- 专利权人： PAMGENE BV
- 当前专利权人： PAMGENE BV
- 当前专利权人地址： NL 's-Hertogenbosch
- 代理机构： Amster, Rothstein & Ebenstein LLP
- 优先权： EP15168371 20150520
- 国际申请： PCT/EP2016/061361 WO 20160520
- 国际公布： WO2016/184999 WO 20161124
- 主分类号： C12Q1/48
- IPC分类号： C12Q1/48 ; G01N33/574
摘要：
The present invention relates to a method for determining or predicting the response of a patient diagnosed with melanoma to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with melanoma to specific medicaments. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in samples of said patients.
公开/授权文献
信息查询
